Long-term effects of niceritrol on serum lipoprotein(a) and lipids in patients with high levels of lipoprotein(a)

Kazunobu Yamauchi, Yoshifumi Tanahashi, Mitsuhiro Okada, Jitsuki Tsuzuki, Akihiko Sato, Kazunari Abe, Haruo Inagaki, Hirotaka Agetsuma, Ritsuo Hattori, Hideo Izawa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The long-term effects of niceritrol on lipoprotein(a) (Lp[a]), lipids, apolipoproteins, and fibrinogen and fibrinolytic factors were evaluated in 20 out-patients who had serum Lp(a) levels higher than 20 mg/dL. The mean (±SE) levels of Lp(a) decreased from 33.6 ± 2.3 mg/dL to 23.5 ± 3.5 mg/dL after 12 months of niceritrol treatment (P < 0.01). Serum levels of triglycerides and apoliprotein E decreased significantly and high-density lipoprotein cholesterol (HDL-C) increased significantly after 12 months (P < 0.05). There were no significant changes overall in fibrinogen and fibrinolytic factors, although fibrinogen concentrations showed a tendency to decrease with treatment. PAI-1 levels decreased significantly (P < 0.05) after 6 months of niceritrol treatment. A significant correlation of percent reduction between Lp(a) and apolipoprotein B levels (P < 0.01) was observed, suggesting that the Lp(a)-lowering effects of niceritrol may be due to niceritrol inhibition of apolipoprotein B synthesis, the major apolipoprotein of Lp(a). The ability of niceritrol to decrease Lp(a) levels and increase HDL-C levels, together with its tendency to lower fibrinogen levels, may help prevent coronary events in patients with high levels of Lp(a).

Original languageEnglish
Pages (from-to)52-59
Number of pages8
JournalClinical therapeutics
Volume17
Issue number1
DOIs
Publication statusPublished - 01-01-1995
Externally publishedYes

Fingerprint

Niceritrol
Lipoprotein(a)
Lipids
Fibrinogen
Serum
Apoprotein(a)
Apolipoproteins B
HDL Cholesterol
Plasminogen Activator Inhibitor 1
Triglycerides
Outpatients
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Yamauchi, Kazunobu ; Tanahashi, Yoshifumi ; Okada, Mitsuhiro ; Tsuzuki, Jitsuki ; Sato, Akihiko ; Abe, Kazunari ; Inagaki, Haruo ; Agetsuma, Hirotaka ; Hattori, Ritsuo ; Izawa, Hideo. / Long-term effects of niceritrol on serum lipoprotein(a) and lipids in patients with high levels of lipoprotein(a). In: Clinical therapeutics. 1995 ; Vol. 17, No. 1. pp. 52-59.
@article{a042ebc66f8c40109471b93b637de75a,
title = "Long-term effects of niceritrol on serum lipoprotein(a) and lipids in patients with high levels of lipoprotein(a)",
abstract = "The long-term effects of niceritrol on lipoprotein(a) (Lp[a]), lipids, apolipoproteins, and fibrinogen and fibrinolytic factors were evaluated in 20 out-patients who had serum Lp(a) levels higher than 20 mg/dL. The mean (±SE) levels of Lp(a) decreased from 33.6 ± 2.3 mg/dL to 23.5 ± 3.5 mg/dL after 12 months of niceritrol treatment (P < 0.01). Serum levels of triglycerides and apoliprotein E decreased significantly and high-density lipoprotein cholesterol (HDL-C) increased significantly after 12 months (P < 0.05). There were no significant changes overall in fibrinogen and fibrinolytic factors, although fibrinogen concentrations showed a tendency to decrease with treatment. PAI-1 levels decreased significantly (P < 0.05) after 6 months of niceritrol treatment. A significant correlation of percent reduction between Lp(a) and apolipoprotein B levels (P < 0.01) was observed, suggesting that the Lp(a)-lowering effects of niceritrol may be due to niceritrol inhibition of apolipoprotein B synthesis, the major apolipoprotein of Lp(a). The ability of niceritrol to decrease Lp(a) levels and increase HDL-C levels, together with its tendency to lower fibrinogen levels, may help prevent coronary events in patients with high levels of Lp(a).",
author = "Kazunobu Yamauchi and Yoshifumi Tanahashi and Mitsuhiro Okada and Jitsuki Tsuzuki and Akihiko Sato and Kazunari Abe and Haruo Inagaki and Hirotaka Agetsuma and Ritsuo Hattori and Hideo Izawa",
year = "1995",
month = "1",
day = "1",
doi = "10.1016/0149-2918(95)80006-9",
language = "English",
volume = "17",
pages = "52--59",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "1",

}

Yamauchi, K, Tanahashi, Y, Okada, M, Tsuzuki, J, Sato, A, Abe, K, Inagaki, H, Agetsuma, H, Hattori, R & Izawa, H 1995, 'Long-term effects of niceritrol on serum lipoprotein(a) and lipids in patients with high levels of lipoprotein(a)', Clinical therapeutics, vol. 17, no. 1, pp. 52-59. https://doi.org/10.1016/0149-2918(95)80006-9

Long-term effects of niceritrol on serum lipoprotein(a) and lipids in patients with high levels of lipoprotein(a). / Yamauchi, Kazunobu; Tanahashi, Yoshifumi; Okada, Mitsuhiro; Tsuzuki, Jitsuki; Sato, Akihiko; Abe, Kazunari; Inagaki, Haruo; Agetsuma, Hirotaka; Hattori, Ritsuo; Izawa, Hideo.

In: Clinical therapeutics, Vol. 17, No. 1, 01.01.1995, p. 52-59.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term effects of niceritrol on serum lipoprotein(a) and lipids in patients with high levels of lipoprotein(a)

AU - Yamauchi, Kazunobu

AU - Tanahashi, Yoshifumi

AU - Okada, Mitsuhiro

AU - Tsuzuki, Jitsuki

AU - Sato, Akihiko

AU - Abe, Kazunari

AU - Inagaki, Haruo

AU - Agetsuma, Hirotaka

AU - Hattori, Ritsuo

AU - Izawa, Hideo

PY - 1995/1/1

Y1 - 1995/1/1

N2 - The long-term effects of niceritrol on lipoprotein(a) (Lp[a]), lipids, apolipoproteins, and fibrinogen and fibrinolytic factors were evaluated in 20 out-patients who had serum Lp(a) levels higher than 20 mg/dL. The mean (±SE) levels of Lp(a) decreased from 33.6 ± 2.3 mg/dL to 23.5 ± 3.5 mg/dL after 12 months of niceritrol treatment (P < 0.01). Serum levels of triglycerides and apoliprotein E decreased significantly and high-density lipoprotein cholesterol (HDL-C) increased significantly after 12 months (P < 0.05). There were no significant changes overall in fibrinogen and fibrinolytic factors, although fibrinogen concentrations showed a tendency to decrease with treatment. PAI-1 levels decreased significantly (P < 0.05) after 6 months of niceritrol treatment. A significant correlation of percent reduction between Lp(a) and apolipoprotein B levels (P < 0.01) was observed, suggesting that the Lp(a)-lowering effects of niceritrol may be due to niceritrol inhibition of apolipoprotein B synthesis, the major apolipoprotein of Lp(a). The ability of niceritrol to decrease Lp(a) levels and increase HDL-C levels, together with its tendency to lower fibrinogen levels, may help prevent coronary events in patients with high levels of Lp(a).

AB - The long-term effects of niceritrol on lipoprotein(a) (Lp[a]), lipids, apolipoproteins, and fibrinogen and fibrinolytic factors were evaluated in 20 out-patients who had serum Lp(a) levels higher than 20 mg/dL. The mean (±SE) levels of Lp(a) decreased from 33.6 ± 2.3 mg/dL to 23.5 ± 3.5 mg/dL after 12 months of niceritrol treatment (P < 0.01). Serum levels of triglycerides and apoliprotein E decreased significantly and high-density lipoprotein cholesterol (HDL-C) increased significantly after 12 months (P < 0.05). There were no significant changes overall in fibrinogen and fibrinolytic factors, although fibrinogen concentrations showed a tendency to decrease with treatment. PAI-1 levels decreased significantly (P < 0.05) after 6 months of niceritrol treatment. A significant correlation of percent reduction between Lp(a) and apolipoprotein B levels (P < 0.01) was observed, suggesting that the Lp(a)-lowering effects of niceritrol may be due to niceritrol inhibition of apolipoprotein B synthesis, the major apolipoprotein of Lp(a). The ability of niceritrol to decrease Lp(a) levels and increase HDL-C levels, together with its tendency to lower fibrinogen levels, may help prevent coronary events in patients with high levels of Lp(a).

UR - http://www.scopus.com/inward/record.url?scp=0028940024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028940024&partnerID=8YFLogxK

U2 - 10.1016/0149-2918(95)80006-9

DO - 10.1016/0149-2918(95)80006-9

M3 - Article

VL - 17

SP - 52

EP - 59

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 1

ER -